Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    18523152 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
Condition: Malignant Melanoma, Metastatic
Interventions: Biological: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF);   Biological: Ipilimumab
2 Active, not recruiting Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
Conditions: Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Biological: Ipilimumab;   Biological: Sargramostim;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years